Valve-in-Valve Replacement Obviates Second Heart Surgery
By HospiMedica International staff writers Posted on 22 Apr 2015 |
Image: The Medtronic CoreValve system (Photo courtesy of Medtronic).
An aortic “valve-in-valve” replacement system helps treat patients who have previously had a tissue aortic valve replacement and are in need of a second one.
The CoreValve artificial heart valve can now be used in patients in need of replacement of a failed tissue aortic valve due to severe native calcific aortic stenosis or failure of a surgical bioprosthetic aortic valve, and who are at high risk for complications associated with traditional open-heart surgery. CoreValve is made of tissue obtained from the heart of a pig; for support, it is attached to a flexible, self-expanding metal frame made of nickel-titanium alloy. To implant the device, it is delivered compressed to the implantation site via transcatheter aortic valve replacement (TAVR).
The procedure involves a catheter threaded through the blood vessels until it reaches the failed tissue aortic valve. It is then released from the end of the catheter, expanding on its own and anchoring itself to the old failed valve. Once the device is in place, it opens and closes properly, restoring the aortic valve function. The CoreValve system, a product of Medtronic (Minneapolis, MN, USA), was approved by the US Food and Drug Administration (FDA) as a replacement valve in patients who are infection-free; do not have a mechanical aortic heart valve; and who can tolerate blood thinners.
“The CoreValve System offers a less invasive treatment option for a significant number of patients with failed tissue aortic valves whose medical teams determine that the risks associated with repeat open-heart surgery are high or extremely high,” said William Maisel, MD, deputy center director for science and chief scientist in the FDA Center for Devices and Radiological Health (CDRH). “The approval is an important expansion of the authorized use of the transcatheter aortic valve replacement technology.”
TAVR aortic valve replacement, without the need for open heart surgery or cardiopulmonary bypass, is faster and less invasive than current open-heart procedures, and has so far been proven effective in high-risk and inoperable patients, and could soon become the standard of care, even in moderate and low surgical risk patients.
Related Links:
Medtronic
The CoreValve artificial heart valve can now be used in patients in need of replacement of a failed tissue aortic valve due to severe native calcific aortic stenosis or failure of a surgical bioprosthetic aortic valve, and who are at high risk for complications associated with traditional open-heart surgery. CoreValve is made of tissue obtained from the heart of a pig; for support, it is attached to a flexible, self-expanding metal frame made of nickel-titanium alloy. To implant the device, it is delivered compressed to the implantation site via transcatheter aortic valve replacement (TAVR).
The procedure involves a catheter threaded through the blood vessels until it reaches the failed tissue aortic valve. It is then released from the end of the catheter, expanding on its own and anchoring itself to the old failed valve. Once the device is in place, it opens and closes properly, restoring the aortic valve function. The CoreValve system, a product of Medtronic (Minneapolis, MN, USA), was approved by the US Food and Drug Administration (FDA) as a replacement valve in patients who are infection-free; do not have a mechanical aortic heart valve; and who can tolerate blood thinners.
“The CoreValve System offers a less invasive treatment option for a significant number of patients with failed tissue aortic valves whose medical teams determine that the risks associated with repeat open-heart surgery are high or extremely high,” said William Maisel, MD, deputy center director for science and chief scientist in the FDA Center for Devices and Radiological Health (CDRH). “The approval is an important expansion of the authorized use of the transcatheter aortic valve replacement technology.”
TAVR aortic valve replacement, without the need for open heart surgery or cardiopulmonary bypass, is faster and less invasive than current open-heart procedures, and has so far been proven effective in high-risk and inoperable patients, and could soon become the standard of care, even in moderate and low surgical risk patients.
Related Links:
Medtronic
Latest Surgical Techniques News
- AR Surgical Technology Translates Complex 2D Medical Imaging to Enhance Accuracy
- Miniaturized Snake-Like Probe Images Cerebral Arteries From Within
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors